News Entropy, UCSF Pre-CTA for Ph2 psilocin vs Lexapro in MDD Entropy signs Pre-CTA with UCSF to develop a US-based Phase 2 trial comparing IV psilocin treatment directly against escitalopram (Lexapro) in MDD.
Patients In schizophrenia care, even the support system needs support After a schizophrenia diagnosis, families must learn how to navigate treatment, respond to symptoms, and communicate effectively.
Digital Callyope's AI-powered solution for mental health practitione... The state of the public’s mental health in the UK and Europe is a serious unmet need.
Patients Stronger together: The future of psychiatry in a changing Eu... Mental disorders account for a significant share of economic cost across EU Member States and the United Kingdom.
R&D 3 big unanswered questions about psychedelics When it comes to psychedelics in the mental health space, there are still some important foundational questions lacking settled answers.
Patients World Bipolar Day: Recognising bipolar I disorder and addres... BD-I is a brain-based condition that affects mood and energy regulation to an extent that disrupts daily life.
News ESC26: Isomab safety evidence on blood vessel growth for CAD Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.